aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Rating of “Hold” by Analysts

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been assigned a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $23.25.

ATYR has been the subject of several recent research reports. HC Wainwright downgraded aTyr Pharma from a “buy” rating to a “neutral” rating in a report on Monday, September 15th. Cantor Fitzgerald lowered shares of aTyr Pharma from an “overweight” rating to a “neutral” rating in a research note on Monday, September 15th. Jones Trading downgraded shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Jefferies Financial Group lifted their price objective on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a “buy” rating in a report on Friday, August 22nd. Finally, Leerink Partnrs downgraded shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th.

Insider Buying and Selling

In related news, Director Paul Schimmel acquired 317,999 shares of the stock in a transaction dated Thursday, October 9th. The stock was purchased at an average cost of $0.94 per share, with a total value of $298,919.06. Following the completion of the purchase, the director directly owned 1,413,023 shares in the company, valued at $1,328,241.62. This trade represents a 29.04% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On aTyr Pharma

Several institutional investors have recently bought and sold shares of the stock. Profund Advisors LLC bought a new position in aTyr Pharma during the 3rd quarter valued at $27,000. California State Teachers Retirement System bought a new stake in shares of aTyr Pharma in the 2nd quarter worth $28,000. Ameritas Investment Partners Inc. purchased a new stake in shares of aTyr Pharma in the second quarter valued at about $45,000. Legal & General Group Plc bought a new position in shares of aTyr Pharma during the second quarter valued at about $49,000. Finally, Prudential Financial Inc. purchased a new position in aTyr Pharma during the second quarter worth about $63,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Trading Up 1.3%

Shares of NASDAQ ATYR opened at $0.78 on Monday. The firm has a market capitalization of $75.99 million, a P/E ratio of -0.93 and a beta of 0.57. The firm’s 50-day moving average price is $0.85 and its 200-day moving average price is $3.27. aTyr Pharma has a 1-year low of $0.64 and a 1-year high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last issued its earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.91 million. Equities research analysts forecast that aTyr Pharma will post -0.91 EPS for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.